Dr. Choueiri on Impact of CABOSUN Results in Renal Cell Carcinoma
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC). Choueiri shared this insight during the 2017 ESMO Congress.
There is potential for cabozantinib to be a frontline option for patients, explains Choueiri. Currently, the agent is approved by the FDA to treat patients who progress after antiangiogenic therapy. Based on the phase II CABOSUN results, this study showed that, by investigator and independent review, there was superiority for the primary endpoint of progression-free survival.
Therefore, cabozantinib does have the potential to be an option in intermediate- and poor-risk patients who are systemic therapy-naïve, he concludes.
